Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9002137 | Biochemical Pharmacology | 2005 | 6 Pages |
Abstract
The present study reveals that cystein2,7 ethyl-amideαCGRP (Cys2,7EtαCGRP), an advertised calcitonin gene-related peptide 2 (CGRP2) receptor subtype-selective agonist, is also a potent agonist for the calcitonin gene-related peptide 1 (CGRP1) receptors natively expressed in the SK-N-MC human neuroblastoma cell line. Cys2,7EtαCGRP and α calcitonin gene-related peptide (αCGRP) promote cyclic AMP accumulation in intact SK-N-MC cells to the same extent with EC50 of 1.6 ± 0.2 and 0.4 ± 0.08 nM, respectively. The antagonist α calcitonin gene-related peptide-8-37 (αCGRP-(8-37)) produces a concentration-dependent rightward shift of the αCGRP- and Cys2,7EtαCGRP concentration-response curves with KB-values (71 ± 33 and 47 ± 21 nM, respectively). The competitive antagonism by αCGRP-(8-37) and the similar KB-values suggests that αCGRP and Cys2,7EtαCGRP stimulate the same receptor. In competition binding studies with [125I]-αCGRP on SK-N-MC cell membranes, Cys2,7EtαCGRP and αCGRP-(8-37) display high affinity for the majority of the binding sites with Ki-values of 0.030 ± 0.013 and 0.60 ± 0.013 nM, respectively. The present findings are at odds with the proclaimed utilization of Cys2,7EtαCGRP as a CGRP2 receptor-selective pharmacological tool. Differences between the agonistic profile of this ligand in this and other experimental systems might be species - or even cell type - dependent.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Christina Nodin, Georges Vauquelin, Bengt von Mentzer,